Clinical Trials Logo

Clinical Trial Summary

This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".


Clinical Trial Description

At present, conventional medical and rehabilitation therapies have not consistently been effective for people with PACS, and in fact some symptoms have been observed to worsen over time. This inconsistency in clinical response has created a need for alternative treatment options to be explored. CBD presents a novel approach that warrants further investigation. After review and approval by an Institutional Review Board (IRB), potential study participants will be recruited from on-line support groups who have identified themselves as persons experiencing post-acute COVID-19 syndrome also known as (long-haulers syndrome). The study will be registered on the www.clincaltrials.gov website and will accept referrals from targeted clinics who refer their patients to the investigational site listed and individuals can also self-refer to the study center team. Subjects will be evaluated weekly using telemedicine procedures. At completion of study, there will be a 7-day and 14-day follow up telemedicine visit to assess for continued benefit and/or re-emergence of symptoms/relapse. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04828668
Study type Interventional
Source Endourage, LLC
Contact Thomas P Young, PhD, NP
Phone 4158951441
Email [email protected]
Status Recruiting
Phase N/A
Start date April 2, 2021
Completion date November 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04333732 - CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION Phase 3
Recruiting NCT04357457 - Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia Phase 3
Recruiting NCT04435795 - Inhaled Ciclesonide for Outpatients With COVID19 Phase 2/Phase 3
Active, not recruiting NCT04357444 - Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19 Phase 2
Withdrawn NCT04426344 - Core Warming of COVID-19 Patients N/A
Recruiting NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Recruiting NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Not yet recruiting NCT04583228 - Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects Phase 1
Active, not recruiting NCT04374487 - Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Phase 2
Recruiting NCT04403243 - COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial Phase 2
Completed NCT04375644 - Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
Completed NCT04394078 - Impact of COVID-19 Pandemic on Depression and Quality of Life
Recruiting NCT04407923 - Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Recruiting NCT04519411 - Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure N/A
Enrolling by invitation NCT04426305 - Community Health Workers Against COVID19 N/A
Recruiting NCT04492514 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation Phase 2
Active, not recruiting NCT04399980 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04403828 - Impact of COVID-19 on Personal Protection Among Dentist in Egypt
Recruiting NCT04401098 - Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak
Completed NCT04407286 - Vitamin D Testing and Treatment for COVID 19 Phase 1